205 related articles for article (PubMed ID: 26872791)
21. Chemotherapy-induced anemia at an urban academic medical center: iron studies and supplementation.
Shord SS; Cuellar S
J Am Pharm Assoc (2003); 2008; 48(4):487-93. PubMed ID: 18653424
[TBL] [Abstract][Full Text] [Related]
22. Questionnaire-based survey on chemotherapy-induced anemia.
Tanaka A; Yoshino I; Makino S; Katsumata N; Takahashi K; Kuwano H; Maehara Y; Nishiyama M
Int J Clin Oncol; 2014; 19(3):411-20. PubMed ID: 24610155
[TBL] [Abstract][Full Text] [Related]
23. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
Wauters I; Vansteenkiste J
Expert Rev Clin Pharmacol; 2011 Jul; 4(4):467-76. PubMed ID: 22114856
[TBL] [Abstract][Full Text] [Related]
24. Blood utilization and hemoglobin levels in cancer patients after label and coverage changes for erythropoiesis-stimulating agents.
Xu H; Kaye JA; Saltus CW; Crawford J; Gasal E; Goodnough LT
Expert Rev Hematol; 2014 Oct; 7(5):617-33. PubMed ID: 25081548
[TBL] [Abstract][Full Text] [Related]
25. Pharmacist collaborative practice agreement for the management of anemia in malignant disease with erythropoiesis-stimulating agents.
Weil E; Oxencis C
Support Care Cancer; 2015 Aug; 23(8):2507-13. PubMed ID: 25971214
[TBL] [Abstract][Full Text] [Related]
26. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
[TBL] [Abstract][Full Text] [Related]
27. Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review.
Henry DH; Langer CJ; McKenzie RS; Piech CT; Senbetta M; Schulman KL; Stepanski EJ
Support Care Cancer; 2012 Sep; 20(9):2089-96. PubMed ID: 22160485
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy-induced anemia and oncologist perception on treatment: results of a web-based survey.
Cortinovis D; Beretta G; Piazza E; Luchena G; Aglione S; Bertolini A; Buzzoni R; Cabiddu M; Carnaghi C; Danova M; Farina G; Ferrari V; Frascaroli M; Reni M; Tansini G;
Tumori; 2013; 99(1):45-50. PubMed ID: 23548999
[TBL] [Abstract][Full Text] [Related]
29. Hemoglobin decline in chemotherapy patients prior to and after policy changes affecting use of erythropoiesis-stimulating agents: 2006-2009.
Hill JW; Cong Z; Hess G; McGarvey N; Nordyke RJ
J Int Med Res; 2012; 40(4):1532-45. PubMed ID: 22971506
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy-induced anemia: the story of darbepoetin alfa.
Vansteenkiste J; Wauters I; Elliott S; Glaspy J; Hedenus M
Curr Med Res Opin; 2013 Apr; 29(4):325-37. PubMed ID: 23323876
[TBL] [Abstract][Full Text] [Related]
31. Impact of a Patient Blood Management Program and an Outpatient Anemia Management Protocol on Red Cell Transfusions in Oncology Inpatients and Outpatients.
Gross I; Trentino KM; Andreescu A; Pierson R; Maietta RA; Farmer S
Oncologist; 2016 Mar; 21(3):327-32. PubMed ID: 26865590
[TBL] [Abstract][Full Text] [Related]
32. An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy.
Montoya VP; Xie J; Williams D; Woodman RC; Wilhelm FE
Support Care Cancer; 2007 Dec; 15(12):1385-92. PubMed ID: 17541653
[TBL] [Abstract][Full Text] [Related]
33. The addition of oral iron improves chemotherapy-induced anemia in patients receiving erythropoiesis-stimulating agents.
Tan J; Du S; Zang X; Ding K; Ginzburg Y; Chen H
Int J Cancer; 2022 Nov; 151(9):1555-1564. PubMed ID: 35639027
[TBL] [Abstract][Full Text] [Related]
34. Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival?
Rocconi RP; Sullivan P; Long B; Blaize M; Brown J; Arbuckle J; Bevis K; Estes JM; Reed E; Finan MA
Int J Gynecol Cancer; 2012 Jun; 22(5):786-91. PubMed ID: 22552832
[TBL] [Abstract][Full Text] [Related]
35. Management of anemia in advanced breast and lung cancer patients in daily practice: results of a French survey.
Ray-Coquard I; Morère JF; Scotté F; Cals L; Antoine EC
Adv Ther; 2012 Feb; 29(2):124-33. PubMed ID: 22314432
[TBL] [Abstract][Full Text] [Related]
36. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
Mafodda A; Giuffrida D; Prestifilippo A; Azzarello D; Giannicola R; Mare M; Maisano R
Support Care Cancer; 2017 Sep; 25(9):2779-2786. PubMed ID: 28391437
[TBL] [Abstract][Full Text] [Related]
37. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
Wauters I; Vansteenkiste J
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1383-90. PubMed ID: 23113603
[TBL] [Abstract][Full Text] [Related]
38. A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia.
Ludwig H; Aapro M; Bokemeyer C; Glaspy J; Hedenus M; Littlewood TJ; Österborg A; Rzychon B; Mitchell D; Beguin Y
Support Care Cancer; 2014 Aug; 22(8):2197-206. PubMed ID: 24659244
[TBL] [Abstract][Full Text] [Related]
39. [Questionnaire-based survey on chemotherapy-induced anemia].
Tanaka A
Gan To Kagaku Ryoho; 2014 Apr; 41(4):421-5. PubMed ID: 24743357
[TBL] [Abstract][Full Text] [Related]
40. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
Aapro M; Spivak JL
Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
